Prediction of nodal involvement in breast cancer based on multiparametric protein analyses from preoperative core needle biopsies of the primary lesion

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3345-3353

  Sauer, Georg ^a   Schneiderhan Marra, Nicole ^b   Kazmaier, Cornelia ^b   Hutzel, Kathrin ^b   Koretz, Karin ^c   Muche, Rainer ^a   Kreienberg, Rolf ^a   Joos, Thomas ^b   Deissler, Helmut ^a,d  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Department of Pathology ^*  (Germany)

^d UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; ESTROGEN RECEPTOR; FAS ANTIGEN; FAS LIGAND; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERCELLULAR ADHESION MOLECULE 1; INTERSTITIAL COLLAGENASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MATRILYSIN; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; RANTES; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CANCER GRADING; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; NEEDLE BIOPSY; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; AGED; BREAST TUMOR; FEMALE; IMMUNOASSAY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROTEIN MICROARRAY;

AGED; BIOPSY, NEEDLE; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOASSAY; LYMPHATIC METASTASIS; MIDDLE AGED; PROTEIN ARRAY ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 50349094778     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4802     Document Type: Article

References (37)

1. Perou CM, Sortie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52.
2. SorlieT, Perou CM.Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA2001;98:10869-74.
3. Carson RT.Vignali DA. Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. J Immunol Methods 1999:227:41-52.
4. Templin MR Stoll D, Schrenk M.Traub PC.Vohringer CF, JoosTO. Protein microarray technology. Trends Biotechnol 2002;20:160-6.
5. Schneiderhan-Marra N, Kirn A, Doettinger A, et al. Protein microarrays - a promising tool for cancer diagnosis. Cancer Genom Proteom 2005;2:37-42.
6. Smith DN, Rosenfield Darling ML, Meyer JE, et alThe utility of ultrasonographically guided large-core needle biopsy: results from 500 consecutive breast biopsies, J Ultrasound Med 2001:20:43-9.
7. Sauer G, Deissler H, Strunz K, et al. Ultrasound- guided large-core needle biopsies of breast lesions: analysis of 962 cases to determine the number of samples for reliable tumour classification Br J Cancer 2005:92:231-5.
8. Luqmani YA. Graham M, Coombes RC. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues, Br J Cancer 1992,66: 273-80.
9. Anandappa SY, Winstanley JH, Leinster S, Green B, Rudland PS, Barraclough R. Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease. Br J Cancer 1994;69:772-6
10. Colomer R, Aparicio J. Montero S, Guzman C. Larrodera L, Cortes-Funes H. Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. Br J Cancer 1997:76:1215-20.
11. Linderholm BK, Lindh B, Beckman L, et al Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1,307 primary breast cancers Clin Breast Cancer 2003.4:340 7
12. Su G, Blaine SA, Qiao D, Fried! A Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation J Biol Chem 2007;282:14906-15
13. Koran R, Das K. Lindy ME, Hameed M. Wieder R Coordinate loss of fibroblast growth factor 2 and laminin 5 expression during neoplastic progression of mammary duct epithelium Hum Pathol 2007,38 154-60.
14. Seymour L. Bezwoda WR. Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer. Breast Cancer Res Treat 1994,32 229-33.
15. Mottolese M, Bugltoni S. Bracalenti C. et al Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer 2000:89 127 32
16. Botti C, Buglioni S, Benevolo M, et al. Altered expression of FAS system is related to adverse clinical outcome in stage l-ll breast cancer patients treated with adjuvant anthracycline-based chemotherapy. Clin Cancer Res 2004;10:1360-5.
17. Uria JA, Stahle-Backdahl M, Seiki M, Fueyo A, Lopez-Otin C. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res 1997;57: 4882-8.
18. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res 2000;6:4823-30.
19. Azenshtein E, Luboshits G, Shina S, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 2002; 62:1093-102.
20. Goldberg-Bittman L, Neumark E, Sagi-Assif O, et al. The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol Lett 2004;92:171-8.
21. Yaal-Hahoshen N, Shina S, Leider-Trejo L, et al. The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res 2006;12:4474-80.
22. van't Veer LJ, Dai H, van deVijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
23. van deVijver MJ, HeYD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
24. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365: 671-9.
25. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004;22:2284-93.
26. Cheng SH, Horng CF.West M, et al. Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol 2006;24:4594-602.
27. Dressman HK, Hans C, Bild A, et al. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 2006;12:819-26.
28. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-72.
29. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004:351: 2817-26.
30. Ellis M, Davis N, Coop A, et al. Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. Clin Cancer Res 2002;8:1155-66.
31. SymmansWF, Ayers M, Clark EA, et al.Total RNAyield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 2003;97:2960-71.
32. Pusztai L, Ayers M, Stec J, et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res 2003;9:2406-15.
33. Jacquemier J, Ginestier C, Rougemont J, et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005;65: 767-79.
34. Ring BZ, Seitz RS, Beck R, et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24:3039-47.
35. Silverstein MJ, Skinner KA, LomisTJ. Predicting axillary nodal positivity in 2,282 patients with breast carcinoma. World J Surg 2001;25:767-72.
36. 1 breast cancer. Ann Surg Oncol 2001;8:432-7.
37. Barth A, Craig PH, Silverstein MJ. Predictors of axillary lymph node metastases in patients withT1 breast carcinoma. Cancer 1997;79:1918-22.